# 1. Financial Performance ## A. Key Figures * **Consolidated Revenue:** **₹193 Cr** (+23% YoY) · **Standalone Revenue:** **₹179 Cr** (+23% YoY) * **Gross Margin:** **71%** standalone (+48 bps) · **71%** consolidated * **Normalized EBITDA Margin:** **35%** standalone (+354 bps) · **33%** consolidated * Normalized EBITDA: ₹63.35 Cr (+42% YoY) · PAT: ₹38.06 Cr (+62% YoY) ## B. Revenue Growth * **Strong Organic Momentum:** Revenue growth underpinned by **21% organic expansion**, with pathology segment delivering robust double-digit growth. * **Inorganic Contribution:** Recent acquisitions (Polo, Vimta, Think Health) added **2% growth**, supporting scale and market reach. ## C. Profit Margins * **Margin Expansion Accelerates:** Standalone EBITDA margin surged over 350 bps, driven by **favorable pricing dynamics**, **improved product mix**, and operating leverage. * **Non-Cash ESOP Impact:** Parent-level ESOPs recorded as non-cash expense; normalized metrics exclude this item for clearer operational performance view. ## D. Cash Flow & Capex * **Strategic Capex Shift:** Transition from reagent rental to full equipment ownership reduces long-term costs and enhances capital efficiency. * **Cost Advantage Locked In:** Debt-free balance sheet and strong cash flow enable lower-cost asset ownership versus peers, reinforcing competitive moat. --- # 2. Volume & Revenue Metrics ## A. Key Figures * **Tests Processed:** **4.69 Cr** (+15% YoY) * Patients Served: 4.6 Mn (+12% YoY) * **Revenue Growth:** **23%** in Q1 FY'26 * **Franchisee Revenue Growth:** **+20%** YoY * **Partnership Revenue Growth:** **+36%** YoY * **Pathology Revenue Growth:** **+25%** YoY * **Radiology Revenue Growth:** **+6%** YoY ## B. Volume Trends & Market Position * **Strong Volume Momentum:** Test and patient volumes expanded at a robust double-digit pace, outperforming the early-to-mid-teens industry growth rate. * **Leadership in Lifestyle Health:** Jaanch continues to gain traction, contributing meaningfully to growth with strong double-digit expansion. * **Seasonality Break:** Q1 revenue growth surpassed Q4 for the first time in years (excluding pandemic periods), indicating improved demand dynamics and execution. ## C. Revenue per Test & Mix Dynamics * **Revenue per Test Uplift Driven by Mix:** Growth in revenue per test and per patient was primarily due to shift toward higher-value tests and new bundled offerings, not broad price increases. * **High-Value Test Expansion:** Launch of premium bundles (e.g., Jaanch Thyroid, Jaanch Diabetes Basic) and growth in **histopathology tests**—with realizations ~**10x** the average—significantly boosted monetization. * **Limited Pricing Power Exerted:** Only **5%–2%** price increases on newly launched tests; routine test prices held flat, underscoring competitive discipline. ## D. Segment Economics * **B2C: High Margin, Small Scale:** Despite capturing **~₹2,000 per test** (vs. ~₹700 cost), the profitable direct-to-consumer segment remains a minor contributor at just **5–6%** of total revenue. --- # 3. Franchise & Partnership Growth ## A. Key Figures * **Active Quarterly Franchisees:** **9,500** in Q1 FY'26 (+1,355 YoY from 8,145) * **Franchise Business Growth:** **20% YoY** in Q1 FY'26 * **Partnerships Business Growth:** **36% overall YoY** (29% ex-API), with **API Pharmacy Diagnostics up 52% YoY** and **Radiology up 6% YoY** * **PharmEasy Partnership Growth:** **30–40% growth** in last two quarters * **Partnership EBITDA Margin:** **33–34%**, in line with company’s normalized 30–35% ## B. Franchise Network * **Accelerated Expansion:** Record franchisee base driven by pay-for-performance incentives and a scalable onboarding engine, with **~100 new franchisees added monthly** and **1,200–1,500 net additions expected in next three quarters**. * **High-Quality Additions:** Over **95% of new franchisees operate established centers** (3–20 years in business), minimizing churn and enabling rapid, capital-light scaling. * **Strong Retention & Performance:** Existing franchisees show **year-on-year doubling in performance**, validating long-term compounding growth from both new and mature outlets. * **Low Franchisee Barriers:** Setup requires only **~200 sq. ft. and ₹3–4 lakh investment**, with minimal, refundable deposits reinvested as wallet credit—reducing entry friction. ## C. Partnership Revenue * **Robust B2B2C Momentum:** Partnerships growth fueled by health check segment expansion and **resurgence in PharmEasy cross-selling**, now back on a **strong growth trajectory** after prior softness. * **Dual Revenue Models:** Business split between **D2C (higher margins)** and **B2B transfer pricing** (e.g., PharmEasy), where Thyrocare earns **lab + logistics fees** under predefined agreements, maintaining **consistent EBITDA margins**. * **Strategic Exclusivity:** **PharmEasy is 100% exclusive**, while other partners (insurers, corporates) are non-exclusive; differentiation driven by **nationwide API integration across 300+ cities**. * **Segment Diversification:** ~**50% of partnership revenue** comes from **corporate health checks and insurers**, with customized packages and pre-policy testing deepening integration into core healthcare workflows. ## D. B2B2C Expansion * **Brand-Led Market Penetration:** Growth supported by targeted brands—**Aarogyam (flagship)**, **Jaanch (lifestyle & preventive care)**, and **Her Check**—expanding reach into high-demand health segments. --- # 4. Product & Service Expansion ## A. Key Figures * **Test Menu Size:** **~1,000 tests** offered · **2,000–3,000 tests** by key competitors (Dr. Lal, Metropolis, Agilus) * **Study Insights:** **1 in 3 fevers** linked to serious infections (dengue, typhoid, malaria, influenza) ## B. Test Menu Growth * **Strategic Expansion:** Menu growth focused on high-demand, volume-driven consolidation of existing tests—such as coagulation, HbA1c graphs, and BioFire panels—rather than broadening for scale. * **Clinical Leadership:** Launched India’s largest HbA1c study and the Jaanch fever panel, reinforcing scientific authority and shaping public health understanding. * **Efficient Innovation:** New packages like Jaanch and Her Check target diabetics, thyroid, and heart patients with no incremental cost, driven by disease prevalence, not test count. * **Technology Parity:** Despite a narrower menu, the company maintains **full technological coverage** across major diagnostic platforms, ensuring competitive service quality. ## C. New Service Launches * **Customer-Centric Enhancements:** Rolled out live reporting, turnaround time tracking, automated reminders, and partner microsites to boost franchisee and D2C satisfaction. ## D. Technology Adoption * **Industry-Standard Capabilities:** All major diagnostic technologies are actively deployed across labs, supporting reliable, scalable operations despite selective test activation. --- # 5. Geographic & Network Reach ## A. Key Figures * **Lab Network:** **40 labs** (including Thyrocare India, Tanzania, Polo, Vimta, partner labs) * **Phlebotomy Network:** **~1,900 phlebotomists** supporting nationwide sample collection * **Central Processing Capacity:** **130,000 samples/day** (combined Mumbai & Delhi CPLs) * **Employee Count:** Increased to **~1,900** post-integration of acquisitions and new labs * **Tanzania Partnerships:** **192+ healthcare facilities** in Dar es Salaam since launch (Apr-24) ## B. Lab Network * **Advanced Diagnostics Capability:** BioFire platform enables **35-hour average report turnaround time**, underpinned by automation and streamlined workflows. * **Network Integration & Expansion:** Full integration of **Polo and Vimta networks** completed; ECG at home rolled out post-Think Health acquisition. * **Scalable Infrastructure Growth:** Geographic reach extended via new partner labs in **Roorkee and Kashmir**, and operational ramp-up of the **Bhagalpur regional lab**. * **Franchise-Led Capacity Build:** Smaller lab setups being expanded through **franchise and storefront partnerships**, enhancing processing scale and future revenue potential. * **Non-Static Growth Model:** Leadership emphasizes continuous evolution—targeting **100% NABL certification** and **Six Sigma standards**—signaling sustained operational transformation. ## C. Regional Expansion * **Strategic North-South Penetration:** Polo Lab acquisition strengthens **North India footprint**, while Wimta Clinical Diagnostics bolsters **South India presence**. ## D. International Presence * **Africa Expansion Ambition:** Thyrocare plans to replicate its **affordable, high-quality domestic diagnostics model in Africa**, targeting improved healthcare access. * **Tanzania Momentum:** Operations launched in **March 2024**, with first test in **April 2024**, now serving **192+ facilities** in Dar es Salaam and pursuing major hospital collaborations. --- # 6. Integration & Acquisition Risks ## A. Key Figures * Quality Target: <3.4 complaints/million (current: 4/million) * **Inorganic Growth Contribution:** **~2%** of total growth * **NABL-Accredited Labs:** **100%** of Thyrocare network (vs. **2%** industry-wide) ## B. M&A Execution * **Integration Success:** Acquisitions completed in FY'25 are now stable and fully embedded, with pruned entities showing strong year-on-year growth. * **Growth Strategy:** Company is prioritizing faster expansion via acquisitions, leveraging proven integration capabilities demonstrated by Vimta and Polo. * **No Cannibalization:** Geographic targeting in regions like Punjab, Himachal, and Uttarakhand avoided overlap; flat run rate post-acquisition not due to cannibalization. ## C. Business Alignment * **Quality Leadership:** Sustained focus on innovation and process rigor has made Thyrocare India’s only fully NABL-accredited national lab chain. * **Clinical Engagement:** Regular advisory board meetings with leading physicians reinforce diagnostic excellence and guide continuous improvement. ## D. Network Churn * **Churn Not Disclosed:** Company reports only net additions; significant churn occurs, often concurrent with acquisition activity. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue & Volume Growth Guidance:** **Mid-teens** maintained * **EBITDA Margin Guidance:** **30%** maintained ## B. Growth Targets * **Cautious Outlook on Momentum:** Guidance held at mid-teens despite strong Q1, as management cites tough H2 prior-year comps and sees reassessment only post H1 results. ## C. Margin Expectations * **Intentional Margin Moderation:** EBITDA margin guidance unchanged at 30%, with excess margins to be reinvested in growth; near-term OPEX pressures are temporary and tied to expansion. ## D. Reinvestment Plans * **Talent Retention via ESOPs:** Thyrocare ESOP program concluded; API ESOP pool expanded to include Thyrocare employees and senior management.